Compare Stocks: ANVS, ALXO, GLSI, and TARA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.94 +2.1%	$2.02	$1.01 ▼ $2.66	$262.73M	0.39	624,569 shs	1.04 million shs
ANVS Annovis Bio	$1.13 -5.5%	$1.72	$1.10 ▼ $5.50	$50.70M	1.24	1.08 million shs	1.89 million shs
GLSI Greenwich LifeSciences	$15.45 +2.6%	$16.09	$7.78 ▼ $34.10	$221.05M	1.47	114,603 shs	74,806 shs
TARA Protara Therapeutics	$3.82 +0.8%	$3.99	$3.02 ▼ $7.82	$223.97M	1.49	323,249 shs	532,026 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+2.11%	-3.48%	-3.48%	+22.78%	+65.81%
ANVS Annovis Bio	-5.86%	-18.63%	-37.85%	-37.67%	-51.09%
GLSI Greenwich LifeSciences	+2.59%	-3.13%	-8.69%	-35.79%	+35.65%
TARA Protara Therapeutics	+0.79%	-3.05%	-1.80%	-2.05%	+22.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.94 +2.1%	$2.02	$1.01 ▼ $2.66	$262.73M	0.39	624,569 shs	1.04 million shs
ANVS Annovis Bio	$1.13 -5.5%	$1.72	$1.10 ▼ $5.50	$50.70M	1.24	1.08 million shs	1.89 million shs
GLSI Greenwich LifeSciences	$15.45 +2.6%	$16.09	$7.78 ▼ $34.10	$221.05M	1.47	114,603 shs	74,806 shs
TARA Protara Therapeutics	$3.82 +0.8%	$3.99	$3.02 ▼ $7.82	$223.97M	1.49	323,249 shs	532,026 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+2.11%	-3.48%	-3.48%	+22.78%	+65.81%
ANVS Annovis Bio	-5.86%	-18.63%	-37.85%	-37.67%	-51.09%
GLSI Greenwich LifeSciences	+2.59%	-3.13%	-8.69%	-35.79%	+35.65%
TARA Protara Therapeutics	+0.79%	-3.05%	-1.80%	-2.05%	+22.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	137.11% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	966.67% Upside
GLSI Greenwich LifeSciences	2.00	Hold	$69.00	346.60% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	587.17% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, GLSI, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/17/2026	TARA Protara Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.54	N/A	N/A	N/A	N/A	-793.81%	-295.32%	11/13/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)

Latest ANVS, ALXO, GLSI, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/11/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	-$0.27	+$0.06	-$0.27	N/A	N/A
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
ANVS Annovis Bio	N/A	3.47	3.47
GLSI Greenwich LifeSciences	N/A	1.54	1.54
TARA Protara Therapeutics	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
GLSI Greenwich LifeSciences	4.16%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
ANVS Annovis Bio	20.80%
GLSI Greenwich LifeSciences	51.47%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
ANVS Annovis Bio	3	42.61 million	33.74 million	Optionable
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable

ANVS, ALXO, GLSI, and TARA Headlines

Recent News About These Companies

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Protara Therapeutics (NASDAQ:TARA) Raised to "Sell" at Wall Street Zen

September 5, 2026 | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Upgraded to Sell at Wall Street Zen

September 5, 2026 | marketbeat.com

Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA

August 29, 2026 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

August 17, 2026 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Issues Negative Forecast for TARA Earnings

August 14, 2026 | marketbeat.com

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

August 14, 2026 | marketbeat.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...

May 15, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, GLSI, and TARA Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.94 +0.04 (+2.11%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.94 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$1.12 -0.07 (-5.46%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$1.14 +0.01 (+0.89%)

As of 09/11/2026 07:43 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Greenwich LifeSciences NASDAQ:GLSI

$15.45 +0.39 (+2.59%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.14 (+0.91%)

As of 09/11/2026 07:49 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Protara Therapeutics NASDAQ:TARA

$3.82 +0.03 (+0.79%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.08 (+2.09%)

As of 09/11/2026 07:30 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, GLSI, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, GLSI, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, GLSI, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, GLSI, and TARA Company Descriptions

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Greenwich LifeSciences NASDAQ:GLSI

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, GLSI, and TARA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, GLSI, and TARA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, GLSI, and TARA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, GLSI, and TARA Company Descriptions

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Greenwich LifeSciences NASDAQ:GLSI

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools